1. Home
  2. CHEB vs ENTA Comparison

CHEB vs ENTA Comparison

Compare CHEB & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHEB
  • ENTA
  • Stock Information
  • Founded
  • CHEB 2024
  • ENTA 1995
  • Country
  • CHEB Singapore
  • ENTA United States
  • Employees
  • CHEB N/A
  • ENTA N/A
  • Industry
  • CHEB
  • ENTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHEB
  • ENTA Health Care
  • Exchange
  • CHEB NYSE
  • ENTA Nasdaq
  • Market Cap
  • CHEB 119.4M
  • ENTA 129.3M
  • IPO Year
  • CHEB 2024
  • ENTA 2013
  • Fundamental
  • Price
  • CHEB $10.12
  • ENTA $5.25
  • Analyst Decision
  • CHEB
  • ENTA Buy
  • Analyst Count
  • CHEB 0
  • ENTA 4
  • Target Price
  • CHEB N/A
  • ENTA $17.25
  • AVG Volume (30 Days)
  • CHEB 28.3K
  • ENTA 759.5K
  • Earning Date
  • CHEB 01-01-0001
  • ENTA 02-05-2025
  • Dividend Yield
  • CHEB N/A
  • ENTA N/A
  • EPS Growth
  • CHEB N/A
  • ENTA N/A
  • EPS
  • CHEB N/A
  • ENTA N/A
  • Revenue
  • CHEB N/A
  • ENTA $67,635,000.00
  • Revenue This Year
  • CHEB N/A
  • ENTA $8.11
  • Revenue Next Year
  • CHEB N/A
  • ENTA N/A
  • P/E Ratio
  • CHEB N/A
  • ENTA N/A
  • Revenue Growth
  • CHEB N/A
  • ENTA N/A
  • 52 Week Low
  • CHEB $9.96
  • ENTA $4.71
  • 52 Week High
  • CHEB $26.25
  • ENTA $17.80
  • Technical
  • Relative Strength Index (RSI)
  • CHEB N/A
  • ENTA 33.14
  • Support Level
  • CHEB N/A
  • ENTA $4.71
  • Resistance Level
  • CHEB N/A
  • ENTA $5.73
  • Average True Range (ATR)
  • CHEB 0.00
  • ENTA 0.35
  • MACD
  • CHEB 0.00
  • ENTA 0.08
  • Stochastic Oscillator
  • CHEB 0.00
  • ENTA 36.99

About CHEB CHENGHE ACQUISITION II CO

Chenghe Acquisition II Co is a blank check company.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Share on Social Networks: